drugset / Trial / NCT01437397

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01437397

Phase 3 Completed 1692 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies. This study will also assess the effects of the fixed dose combination in terms of COPD symptoms, disease related health status and the long-term safety and tolerability of the fixed dose combination. This study will include a 24 week treatment period, preceding by a run-in period, followed by a two week follow up visit. All patients will be randomized to one of four treatment arms or placebo.

Timeline

Start
2011-09
Primary completion
2013-02
Completion
2013-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aclidinium Small molecule 400 ug Inhaled
Subject Aclidinium Bromide/Formoterol Fumarate Unknown Inhaled
Comparator Formoterol Other / unclassified 12 ug Inhaled